DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Milrinone During Living Donor Hepatectomy

Information source: Seoul National University Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hepatectomy

Intervention: milrinone (Drug); placebo (Drug)

Phase: N/A

Status: Completed

Sponsored by: Seoul National University Hospital

Summary

Maintaining a low central venous pressure during living donor hepatectomy is routine practice. The investigators tried to test the hypothesis that using milrinone to maintain a low central venous pressure (CVP) during is associated with a superior surgical field and less blood loss.

Clinical Details

Official title: Effect of Milrinone During Living Donor Hepatectomy Using a Low Central Venous Pressure Technique

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome: condition of surgical field

Secondary outcome: the use of vasopressor and diuretics to maintain hemodynamic stability and low CVP status, respectively

Eligibility

Minimum age: 19 Years. Maximum age: 55 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Living liver donors

Exclusion Criteria:

- Donors with concurrent cardiac, pulmonary, and urologic disease

- Hepatectomy performed laparoscopically

Locations and Contacts

Seoul National University Hospital, Seoul 110-744, Korea, Republic of
Additional Information

Starting date: January 2008
Last updated: August 26, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017